Clever Leaves (CLVR) Competitors

Clever Leaves (NASDAQ:CLVR) and Scopus BioPharma (NASDAQ:SCPS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, community ranking, valuation and earnings.

Does the MarketBeat Community believe in CLVR or SCPS?

Clever Leaves received 11 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 81.25% of users gave Clever Leaves an outperform vote.

Company	Underperform	Outperform
Clever Leaves	Outperform Votes 13 81.25%	Underperform Votes 3 18.75%
Scopus BioPharma	Outperform Votes 2 100.00%	Underperform Votes No Votes

Do insiders and institutionals believe in CLVR or SCPS?

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has more volatility and risk, CLVR or SCPS?

Clever Leaves has a beta of 2803.28, suggesting that its share price is 280,228% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500.

Is CLVR or SCPS more profitable?

Company	Net Margins	Return on Equity	Return on Assets
Clever Leaves	N/A	N/A	N/A
Scopus BioPharma	N/A	N/A	N/A

Does the media refer more to CLVR or SCPS?

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Clever Leaves	Neutral
Scopus BioPharma	Neutral

Which has better earnings and valuation, CLVR or SCPS?

Scopus BioPharma has lower revenue, but higher earnings than Clever Leaves.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clever Leaves	$17.42M	0.00	-$17.90M	-$11.31	0.00
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

Summary

Clever Leaves beats Scopus BioPharma on 5 of the 7 factors compared between the two stocks.